Characterization of Thyroid Cancer Cell Lines in Murine Orthotopic and Intracardiac Metastasis Models

Hormones and Cancer

Volumn 6, Issue 2-3, 2015, Pages 87-99

  Morrison, Jennifer A ^a   Pike, Laura A ^a   Lund, Greg ^a   Zhou, Qiong ^a   Kessler, Brittelle E ^a   Bauerle, Kevin T ^a   Sams, Sharon B ^a   Haugen, Bryan R ^a   Schweppe, Rebecca E ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CANCER TRANSPLANTATION; DISEASE MODEL; HEART TUMOR; HUMAN; METASTASIS; MOUSE; NUDE MOUSE; PATHOLOGY; PROCEDURES; SECONDARY; THYROID TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HEART NEOPLASMS; HETEROGRAFTS; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; THYROID NEOPLASMS;

EID: 84939981131     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-015-0219-0     Document Type: Article

References (46)

1. Ahn SH, Henderson Y, Kang Y, Chattopadhyay C, Holton P, Wang M, Briggs K, Clayman GL (2008) An orthotopic model of papillary thyroid carcinoma in athymic nude mice. Arch Otolaryngol Head Neck Surg 134(2):190–197. doi:10.1001/archoto.2007.36
2. Alfano RW, Leppla SH, Liu S, Bugge TH, Ortiz JM, Lairmore TC, Duesbery NS, Mitchell IC, Nwariaku F, Frankel AE (2010) Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Mol Cancer Ther 9(1):190–201. doi:10.1158/1535-7163.MCT-09-0694
3. Antonello ZA, Nucera C (2014) Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF or wild-type BRAF. Oncogene 33(47):5397–5404. doi:10.1038/onc.2013.544
4. Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR (2014) Nuclear factor kappaB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab 99(8):E1436–E1444. doi:10.1210/jc.2013-3636
5. Bellelli R, Castellone MD, Garcia-Rostan G, Ugolini C, Nucera C, Sadow PM, Nappi TC et al (2012) FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocr Relat Cancer 19(5):695–710. doi:10.1530/ERC-12-0031
6. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940):319–328. doi:10.1016/S0140-6736(14)60421-9
7. Cardiff RD, Miller CH, Munn RJ (2014) Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc 6:655–658. doi:10.1101/pdb.prot073411
8. Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE (2012) Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res 18(13):3580–3591. doi:10.1158/1078-0432.CCR-11-3359
9. Chang JW, Kang SU, Choi JW, Shin YS, Baek SJ, Lee SH, Kim CH (2014) Tolfenamic acid induces apoptosis and growth inhibition in anaplastic thyroid cancer: involvement of nonsteroidal anti-inflammatory drug-activated gene-1 expression and intracellular reactive oxygen species generation. Free Radic Biol Med 67:115–130. doi:10.1016/j.freeradbiomed.2013.10.818
10. Garg M, Okamoto R, Nagata Y, Kanojia D, Venkatesan,T. A. M, G. D. Braunstein et al. (2014) Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft. J Clin Endocrinol Metab jc20142359. doi:10.1210/jc.2014-2359
11. Grant CS, Thompson G (2011) Anaplastic thyroid carcinoma: hope on the horizon? Surgery 150(6):1220–1221. doi:10.1016/j.surg.2011.10.006
12. Gule MK, Chen Y, Sano D, Frederick MJ, Zhou G, Zhao M, Milas ZL et al (2011) Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 17(8):2281–2291. doi:10.1158/1078-0432.CCR-10-2762
13. Gunda V, Bucur O, Varnau J, Vanden Borre P, Bernasconi MJ, Khosravi-Far R, Parangi S (2014) Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis 5:e1104. doi:10.1038/cddis.2014.78
14. Gunda V, Frederick DT, Bernasconi MJ, Wargo JA, Parangi S (2014) A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression. Thyroid 24(8):1241–1250. doi:10.1089/thy.2013.0680
15. Henderson YC, Ahn SH, Clayman GL (2009) Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040. Arch Otolaryngol Head Neck Surg 135(4):347–354. doi:10.1001/archoto.2009.17
16. Henderson YC, Ahn SH, Kang Y, Clayman GL (2008) Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res 14(15):4908–4914. doi:10.1158/1078-0432.CCR-07-1772
17. Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M et al. (2015) Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab jc20142624. doi:10.1210/jc.2014-2624
18. Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL (2010) MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther 9(7):1968–1976. doi:10.1158/1535-7163.MCT-10-0062
19. Henderson YC, Toro-Serra R, Chen Y, Ryu J, Frederick MJ, Zhou G, Gallick GE, Lai SY, Clayman GL (2014) Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck 36(3):375–384. doi:10.1002/hed.23316
20. Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T (2005) Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 7(4):R444–R454. doi:10.1186/bcr1026
21. Jeong WJ, Mo JH, Park MW, Choi IJ, An SY, Jeon EH, Ahn SH (2011) Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation. Cancer Biol Ther 12(5):458–465
22. Kang Y (2009) Analysis of cancer stem cell metastasis in xenograft animal models. In: Yu JS (ed) Methods in molecular biology. Humana Press, New York
23. Kim S, Park YW, Schiff BA, Doan DD, Yazici Y, Jasser SA, Younes M, Mandal M, Bekele BN, Myers JN (2005) An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res 11(5):1713–1721. doi:10.1158/1078-0432.CCR-04-1908
24. Lee SE, Lee JU, Lee MH, Ryu MJ, Kim SJ, Kim YK, Choi MJ et al. (2013) RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer. Oncogenesis 2:e55. doi:10.1038/oncsis.2013.12
25. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK, Xing M (2013) Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20(4):603–610. doi:10.1530/ERC-13-0210
26. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK et al (2014) TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 99(6):E1130–E1136. doi:10.1210/jc.2013-4048
27. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R et al (2014) TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 99(5):E754–E765. doi:10.1210/jc.2013-3734
28. Mo JH, Choi IJ, Jeong WJ, Jeon EH, Ahn SH (2012) HIF-1alpha and HSP90: target molecules selected from a tumorigenic papillary thyroid carcinoma cell line. Cancer Sci 103(3):464–471. doi:10.1111/j.1349-7006.2011.02181.x
29. Morrison JA, Pike LA, Sams SB, Sharma V, Zhou Q, Severson JJ, Tan A-C, Wood WM, Haugen BR (2014) Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol Cancer in press
30. Muzza M, Colombo C, Rossi S, Tosi D, Cirello V, Perrino M, De Leo S et al (2015) Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Mol Cell Endocrinol 399:288–295. doi:10.1016/j.mce.2014.10.019
31. Nehs MA, Nagarkatti S, Nucera C, Hodin RA, Parangi S (2010) Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. Surgery 148(6):1154–1162. doi:10.1016/j.surg.2010.09.001, discussion 1162
32. Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, Parangi S (2012) Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology 153(2):985–994. doi:10.1210/en.2011-1519
33. Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V, Parangi S (2009) A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid 19(10):1077–1084. doi:10.1089/thy.2009.0055
34. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS et al (2011) Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 16(3):296–309. doi:10.1634/theoncologist. 2010-0317
35. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D et al (2010) B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA 107(23):10649–10654. doi:10.1073/pnas.1004934107
36. Reeb AN, Li W, Sewell W, Marlow LA, Tun HW, Smallridge RC, Copland JA, Spradling K, Chernock R, Lin RY (2014) S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma. J Clin Endocrinol Metab 100 (2):E232–E242. doi:10.1210/jc.2014-2988
37. Ribeiro FR, Meireles AM, Rocha AS, Teixeira MR (2008) Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples. BMC Cancer 8:371. doi:10.1186/1471-2407-8-371
38. Sandulache VC, Skinner HD, Wang Y, Chen Y, Dodge CT, Ow TJ, Bankson JA, Myers JN, Lai SY (2012) Glycolytic inhibition alters anaplastic thyroid carcinoma tumor metabolism and improves response to conventional chemotherapy and radiation. Mol Cancer Ther 11(6):1373–1380. doi:10.1158/1535-7163.MCT-12-0041
39. Scarpino S, Duranti E, Giglio S, Di Napoli A, Galafate D, Del Bufalo D, Desideri M, Socciarelli F, Stoppacciaro A, Ruco L (2013) Papillary carcinoma of the thyroid: high expression of COX-2 and low expression of KAI-1/CD82 are associated with increased tumor invasiveness. Thyroid 23(9):1127–1137. doi:10.1089/thy.2011.0421
40. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA et al (2008) Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93(11):4331–4341. doi:10.1210/jc.2008-1102
41. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics. CA Cancer J Clin 65(1):5–29. doi:10.3322/caac.21254
42. Smallridge RC, Copland JA (2010) Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 22(6):486–497. doi:10.1016/j.clon.2010.03.013
43. Vanden Borre P, McFadden DG, Gunda V, Sadow PM, Varmeh S, Bernasconi M, Jacks T, Parangi S (2014) The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma. Thyroid 24(4):705–714. doi:10.1089/thy.2013.0483
44. Wood WM, Sharma V, Bauerle KT, Pike LA, Zhou Q, Fretwell DL, Schweppe RE, Haugen BR (2011) PPARgamma promotes growth and invasion of thyroid cancer cells. PPAR Res 2011:171765. doi:10.1155/2011/171765
45. Xing M (2013) Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 13(3):184–199. doi:10.1038/nrc3431
46. Zhang L, Gaskins K, Yu Z, Xiong Y, Merino MJ, Kebebew E (2014) An in vivo mouse model of metastatic human thyroid cancer. Thyroid 24(4):695–704. doi:10.1089/thy.2013.0149